The drug and biotech sector bounced back this month after struggling this year due to tariff and pricing fears and broader macro headwinds. The recovery was propelled by Pfizer’s landmark drug-pricing deal with Trump, wherein Pfizer was granted a three-year exemption from tariffs on pharmaceutical imports in exchange for price cuts and discounts on some of its drugs and increased U.S. manufacturing investment. The PFE-Trump deal, along with a recent surge in M&A activity, triggered a recovery in the overall ...